A real-time, in vivo imaging platform guides surgeons during cancer surgery. This breakthrough technology illuminates cancer cells and other diseased tissues at the molecular level, allowing surgeons to take action and better patient outcomes. Currently, there is a technological gap at the molecular level. Surgeries are being completed without being able to distinguish between healthy and cancerous tissue. This technology solves the problem, so surgeons can complete their surgeries with the ability to differentiate between tissues and have better accuracy in removing all cancerous tissue. Currently, the company is focused on breast cancer in their testings, but want to continue…
Author: Brett Johnson
Clifford Reid is the founding CEO of Travera. Previously, Dr. Reid was the founding Chairman, President and Chief Executive Officer of Complete Genomics (NASDAQ:GNOM), a leading developer of whole human genome DNA sequencing technologies and services. Dr. Reid is on the Visiting Committee of the Biological Engineering Department at the Massachusetts Institute of Technology (MIT), a member of the MIT Corporation Development Committee, and an advisor to Warburg Pincus. He earned a S.B. in Physics from MIT, an MBA from the Harvard Business School, and a Ph.D. in Management Science and Engineering from Stanford University. Brett Johnson: So tell us…
Travera’s new technology can predict how patients will respond to hundreds of different drugs or drug combinations before the patients even take the drugs. Their new measurement tool, the Suspended Microchannel Resonator (SMR), reveals cancer cells’ responses to effective drugs faster than ever before. Travera tests on-label drugs, off-label drugs, and investigational drugs, to maximize drug quality and effectiveness for patients and to save them from unnecessary toxicity. By doing so, Travera can pinpoint the right drugs within <2 days, even though it will take many weeks to work in the patient’s body, and thus, is moving oncology from being…
Mature pipeline of biopharmaceuticals for rare diseases. Government funding for biodefense business. Soligenix is a two-segment business. They have a biotherapeutics rare disease segment focused on cancer, cancer supportive care and inflammation and a separate vaccine/biodefense segment of business funded entirely by the U.S. government, focused on medical countermeasures for military and civilian use. See Soligenix’s Profile.
June 7, 2019, by NCI Staff Smoldering myeloma is a slow-growing type of multiple myeloma, a form of cancer in which abnormal plasma cells (purple) make too much of a single type of antibody. The drug lenalidomide (Revlimid) may delay the development of multiple myeloma in individuals with smoldering myeloma that is at high risk of progressing to cancer, according to preliminary results from a clinical trial. Smoldering myeloma is a precancerous condition that alters certain proteins in blood and/or increases plasma cells in bone marrow, but it does not cause symptoms of disease. About half of those diagnosed with the condition, however, will develop multiple myeloma within 5 years.…
JUNE 4, 2019 NFCR WRITER DAVID PERRY BLOG Ask any parent about their child fighting cancer and words like “nightmare” and “helpless” will almost certainly be part of the conversation. Within pediatric cancer medicine, the entire field faces the brutal reality that chemotherapy, surgery and most other cancer treatments are not designed for children. This can be somewhat understandable, since cancer is predominantly an adult disease. There are more than 100 kinds of cancer, yet the American Cancer Society lists just eight as common among children. Yet pediatricians cannot, on the fly, convert adult therapies to use for child patients. Use too little of…
The latest Annual Report to the Nation on the Status of Cancer finds that, for all cancer sites combined, cancer death rates continued to decline in men, women, and children in the United States from 1999 to 2016. Overall cancer incidence rates, or rates of new cancers, decreased in men from 2008 to 2015, after increasing from 1999 to 2008, and were stable in women from 1999 to 2015. In a special section of the report, researchers looked at cancer rates and trends in adults ages 20 to 49. The annual report is a collaborative effort among the National Cancer…
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is currently an unmet medical need. Soligenix is a biotherapeutic business segment dedicated to the development of products for orphan diseases and areas where there are currently no drug therapies approved, such as Cutaneous T-Cell Lymphoma, oral mucositis, and pediatric Crohn’s disease. They are now conducting two Phase 3 clinical trials with multiple data reads through 2019 and early 2020. Their first Phase 3 trial, for cutaneous T-cell Lymphoma (or CTCL), used a novel photodynamic therapy for the first-line treatment of this…